Belite Bio advances FDA rolling submission for Stargardt disease candidate

Belite Bio (NASDAQ:BLTE) reported its unaudited financial results and operational milestones for the first quarter ended March 31, 2026.

The period marked an operational transition for the company as it initiated regulatory filings for its lead candidate and secured the core commercial leadership required for a potential market launch.

In April 2026, the San Diego-based biotechnology firm commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for its primary oral therapeutic candidate, tinlarebant, for the treatment of Stargardt disease type 1 (STGD1).

Benefiting from an active FDA Breakthrough Therapy Designation, the rolling submission framework allows regulators to review completed sections of the application continuously, with full completion of the file projected within the second quarter of 2026.

Financially, Belite Bio reported a GAAP net loss of $26.9 million, or $0.68 per share, for the three-month period, compared to a GAAP net loss of $14.3 million in the opening quarter of 2025.

On a non-GAAP basis, excluding share-based compensation, the net loss settled at $13.7 million, outperforming consensus analyst estimates for a broader deficit.

The widening year-over-year net loss reflects an intentional ramp-up in late-stage operational activities.

First-quarter research and development expenses rose to $15.7 million, up from $9.4 million a year ago, driven by active pharmaceutical ingredient manufacturing and escalating clinical management fees.

Concurrently, selling, general, and administrative expenses increased to $17 million from $6.1 million in the prior-year period, largely due to ongoing workforce expansion.

To support future market execution, the company confirmed it has completed the hiring of all key commercial leadership positions.

The corporate cash position remains heavily capitalized to support late-stage commercialization timelines.

As of March 31, 2026, Belite Bio maintained total liquid reserves of $798.6 million, split contextually between $276.4 million held in cash and cash equivalents alongside $522.2 million deployed in highly liquid short-term U.S. Treasury bills and notes.

This asset pool generated $5.7 million in interest and other non-operating income during the single quarter.

Clinical execution across the broader ophthalmology pipeline sustained a steady cadence during the quarter.

The definitive Phase 3 DRAGON trial evaluating tinlarebant in adolescent patients with STGD1 has concluded its evaluation cycles.

Meanwhile, the parallel global DRAGON II Phase 2/3 trial and the pivotal Phase 3 PHOENIX trial—which investigates the molecule's efficacy in slowing lesion growth for patients with geographic atrophy secondary to advanced dry age-related macular degeneration—have both completed their target patient enrollment quotas.